In 2007, the US Supreme Court set a new test for declaratory judgment actions in MedImmune. Its decision continues to have a profound impact on trade mark cases, explain Bobby Ghajar and Carolyn Toto.
The Court of Appeal recently heard a case relating to Genentech's patent, which claimed the use of human vascular endothelial growth factor (hVEGF) antagonists for the treatment of non-cancerous diseases which are...more
In 2007, the United States Supreme Court ruled that patent licensees could challenge their obligation to pay patent license royalties under a license agreement without first breaching the license agreement by halting royalty...more
On May 10, 2013, in Sanofi-Aventis Deutschland GmbH v. Genentech, Inc., the U.S. Court of Appeals for the Federal Circuit (Rader, Dyk, Reyna*) affirmed the district court's denial of Genentech's motion to enjoin Sanofi from...more
Just after I posted about the awesome power of federal courts to enjoin other cases, the Federal Circuit reminds us the power is not absolute....more
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Bristol-Myers Squibb Co. v. Genentech, Inc. et al. 3:13-cv-02045; filed May 3, 2013 in the Northern District of...more
In This Issue:
Eli Lilly and Company et al. v. Genentech, Inc. et al.; Depomed Inc. v. Watson Laboratories Inc. - Florida et al.; Eli Lilly and Company v. Accord Healthcare Inc., USA; Endo Pharmaceuticals Inc. et al....more